Drug Trial News

RSS

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

11 Dec 2017

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

Drug improves disease-free, overall survival after hematopoietic stem cell transplants

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

11 Dec 2017

Novel compound along with checkpoint inhibitors may enhance immune response in melanoma patients

A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.

8 Dec 2017

PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

8 Dec 2017

Study shows safety, efficacy of cystic fibrosis drug in children between 1 to 2 years of age

Ann & Robert H. Lurie Children's Hospital of Chicago is one of the study sites in the open label Phase 3 study that showed safety and effectiveness of the cystic fibrosis drug Kalydeco (ivacaftor) in children ages 1 to 2 years.

8 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

Investigational ZPIV vaccine found to be safe and immunogenic in trial participants

The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials.

5 Dec 2017

New drugs Erenumab and Fremanezumab show promise for migraine

Migraine headaches affect thousands of Americans and millions worldwide. There are several medications that are being prescribed for migraines and for many these do not work well.

30 Nov 2017

New immunotherapy study shows positive results in chronic migraine sufferers

A new study of fremanezumab, an immunotherapy that counteracts one of the molecules released during migraine, was found successful in reducing the number of days that chronic migraine sufferers experienced headaches.

30 Nov 2017

Synthetic cannabis-like drug found to be safe and effective in treating sleep apnea

A synthetic cannabis-like drug in a pill was safe and effective in treating obstructive sleep apnea in the first large multi-site study of a drug for apnea funded by the National Institutes of Health. The study was conducted at Northwestern Medicine and the University of Illinois at Chicago.

28 Nov 2017

New cancer drug begins clinical trial in human patients with rare brain tumor

A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain.

28 Nov 2017

New study tests pain treatment in humans

Nerve growth factor signals through receptors of the tropomyosin-related kinase (Trk) family, and research in animals has shown that inhibitors of Trks A, B, and C can reduce pain.

27 Nov 2017

Researchers question exclusion of people with prior cancer history from clinical trials

A quarter of newly diagnosed cancer patients 65 or older are survivors who had a prior cancer – often preventing them from participating in clinical trials, researchers from UT Southwestern's Simmons Cancer Center have found.

22 Nov 2017

Trial shows apple allergen as effective treatment option for birch pollen-related apple allergy

The food allergy, which is related to birch pollen, is a very common attendant phenomenon associated with birch pollen allergy - indeed around 70% of those with a birch pollen allergy are also allergic to apples. That amounts to around 280,000 people in Austria.

20 Nov 2017

Study: Alectinib 600 mg more effective than standard therapy in Asian ALK positive NSCLC patients

A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.

20 Nov 2017

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.

20 Nov 2017

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

A randomized trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.

20 Nov 2017

Machine learning could detect therapeutic effects with greater sensitivity than conventional tests

Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published in Brain.

15 Nov 2017

PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease

Patients with peripheral artery disease (PAD) are at high risk of heart attack, stroke and cardiovascular death. In addition, PAD patients can suffer major adverse limb events, such as acute limb ischemia - the equivalent of a heart attack in the leg - that can lead to limb loss.

14 Nov 2017

Drug Trial News

Combination of chemotherapy and targeted drug improves response in younger CLL patients

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

Drug improves disease-free, overall survival after hematopoietic stem cell transplants

Novel compound along with checkpoint inhibitors may enhance immune response in melanoma patients

PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations

Study shows safety, efficacy of cystic fibrosis drug in children between 1 to 2 years of age

New first line combination therapy shows promising results in patients with advanced NSCLC

Investigational ZPIV vaccine found to be safe and immunogenic in trial participants

New drugs Erenumab and Fremanezumab show promise for migraine

New immunotherapy study shows positive results in chronic migraine sufferers

Synthetic cannabis-like drug found to be safe and effective in treating sleep apnea

New cancer drug begins clinical trial in human patients with rare brain tumor

New study tests pain treatment in humans

Researchers question exclusion of people with prior cancer history from clinical trials

Trial shows apple allergen as effective treatment option for birch pollen-related apple allergy

Study: Alectinib 600 mg more effective than standard therapy in Asian ALK positive NSCLC patients

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Machine learning could detect therapeutic effects with greater sensitivity than conventional tests

PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News